The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

"PEPFAR funding protection offers “hope” for people living with HIV" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The U.S. Senate has opened debate on a $9 billion rescission bill to claw back foreign aid and other funding not aligned with ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...